HEART-FID - A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure With Iron Deficiency
The primary objective of this study is to determine the efficacy and safety of iron therapy using intravenous (IV) ferric carboxymaltose (FCM), relative to placebo, in the treatment of participants in heart failure with iron deficiency and with a reduced ejection fraction.
Principal Investigator
Edward Chu, MD
Contact
Virginia Barch, RN, MSN, CCRC
757-594-4508
[email protected]
Locations
Riverside Regional Medical Center
500 J. Clyde Morris Blvd.
Newport News, VA 23601
Status
Recruiting
Category
Cardiology
Study #